SeaStar Medical and LMF complete business combination

LMF Acquisition Opportunity Renamed as Seastar Medical Holdings

Starfish Medical Holdings Inc. common stock and warrants to begin trading on Nasdaq under the new ticker symbols “ICU” and “ICUCW”

DENVER & TAMPA, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) — SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of excessive inflammation in vital organs, announced today that it has completed Previously announced business combination with LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ: LMFA). The business combination closes on October 28, 2022.

Following the closing of the business combination, LMF Acquisition Opportunities, Inc. will be renamed SeaStar Medical Holding Corporation and will operate under the same management team as SeaStar Medical, led by Chief Executive Officer Eric Schlorff. Caryl Baron will serve as interim chief financial officer. Starfish Medical Holdings’ common stock and warrants are expected to begin trading on the Nasdaq on October 31, 2022, under the new ticker symbols “ICU” and “ICUCW,” respectively.

The transaction was unanimously approved by the Boards of Seastar Medical and LMAO. Holders of SeaStar Medical’s majority voting rights have approved the merger. LMAO shareholders approved the transaction at a special meeting of LMAO shareholders held on October 18, 2022, with more than 96% of the votes in favor of the transaction.

Eric Schlorff, President and CEO of SeaStar Medical Holding Corporation, said: “As a public company, we are excited to begin the next phase of our journey. This transaction provides us with additional resources to advance our selective cells A transplant device (SCD) to help patients suffering from the devastating consequences of excessive inflammation. We have submitted a Humanitarian Device Exemption (HDE) application to the U.S. Food and Drug Administration (FDA) for pediatric Initiate a pivotal study of SCD in adults with acute kidney injury (AKI) in Q1 2023. As a public company, we will be better positioned to advance these programs.”

Bruce M. Rodgers, Chairman and CEO of LM Funding, the sponsor of LMF Acquisition Opportunities, commented, “We are proud of the hard work over the past few years that has brought us to this very important milestone. We are very pleased that this transaction has been secured by LMF The overwhelming support of Acquisition shareholders and believe it will unlock significant value for shareholders of LM Funding and SeaStar Medical. We look forward to supporting SeaStar Medical Holding Corporation as they continue to advance potentially life-saving therapies as a public company.”

Maxim Group LLC acted as exclusive financial advisor and Morgan Lewis & Bockius LLP acted as legal advisor to SeaStar Medical in connection with the business combination. Foley & Lardner LLP acted as legal counsel to LMAO in connection with the business combination. Ellenoff Grossman & Schole LLP acted as legal counsel to Maxim Group LLC.

About SeaStar Medical, Inc.

Denver-based SeaStar Medical is a medical technology company focused on redefining how extracorporeal therapy reduces the effects of excessive inflammation on vital organs. SeaStar Medical’s new technologies rely on science and innovation to provide life-saving solutions for critically ill patients. It is developing and commercializing ex vivo therapies targeting effector cells that drive systemic inflammation, cause direct tissue damage and secrete a range of pro-inflammatory cytokines that initiate and propagate an imbalanced immune response. For more information, please visit or visit us on LinkedIn or Twitter.

About LM Funding America, Inc.

LM Funding America, Inc. (Nasdaq: LMFA) and its subsidiaries are a cryptocurrency mining business that started bitcoin mining operations in September 2022. The company also operates a technology-based professional finance firm for nonprofit community associations (associations) primarily located in Florida, as well as Washington, Colorado, and Illinois, by funding the associations’ rights to a certain portion of delinquent accounts, which are Accounts are selected by the association based on an unpaid association assessment.

forward-looking statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, but are not limited to, expectations of SeaStar Medical Holding Corporation, LMAO and SeaStar Medical regarding the proposed business combination between LMAO and SeaStar Medical, including statements regarding the benefits of the transaction, SeaStar Medical Holding Corporation’s realization of value for its stakeholders capabilities, SeaStar Medical’s implied valuation, the products offered by SeaStar Medical Holding Corporation and the markets in which it operates, and the expected timing of regulatory approval of SeaStar Medical Holding Corporation’s products. Words such as “believe,” “project,” “anticipate,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” etc. , “will”, “will”, “will be”, “will continue”, “will likely result” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are projections, forecasts and other statements about future events that are based on current expectations and assumptions and are therefore subject to significant risks and uncertainties that could cause actual results to differ materially from those anticipated. Most of these factors are beyond the control of LMAO and SeaStar Medical and are difficult to predict. Factors that could cause actual future events to differ materially from expected results include, but are not limited to: (i) the inability to recognize expected benefits from a business combination, which may be affected by competition and other factors. the combined company’s ability to grow and manage growth profitability and retain key employees, (ii) costs associated with the business combination, (iii) the outcome of any legal action that may be brought against SeaStar Medical Holding Corporation to declare the business combination complete, (x ) the ability to maintain a listing of its securities on the Nasdaq, (iv) the ability to implement business plans, forecasts and other expectations after the closing of the proposed business combination, and to identify and realize additional opportunities, (v) the intense competition in which SeaStar Medical operates the risk of downturn and the possibility of rapid change in the industry holding company operations, (vi) the risk that SeaStar Medical Holding Corporation and its current and future collaborators will not be able to successfully develop and commercialize its products or services, or encounter difficulties in doing so. subject to significant delays, including failure to obtain applicable product approvals from federal and state regulatory agencies, (vii) the risk that SeaStar Medical Holding Corporation may never achieve or maintain profitability; (viii) SeaStar Medical Holding Corporation may need to raise additional capital to execute its the risk of business plans, many of which are not available on acceptable terms or at all; (ix) the risk that third-party suppliers and manufacturers will not be able to meet their obligations in full and in a timely manner, (x) in connection with SeaStar Medical’s products and services risk of product liability or regulatory action or litigation, (xi) SeaStar Medical Holding Corporation’s inability to secure or protect its intellectual property rights, and (xiii) other risks and uncertainties identified from time to time in LMAO’s registration statement on Form S-4 , as amended (File No. 333-264993), including those in the “Risk Factors” section therein and in other LMAO filings with the SEC. The factors listed above are not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and SeaStar Medical, LMAO and SeaStar Medical Holding Corporation undertake no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Media Relations Contact:
Patty Caballero
Phone: 862.216.7523

SeaStar Medical Investor Contact:
Jenny Thomas
Phone: (833) 475-8247

LM Funding Investor Contact:
Crescendo Communications LLC
david waldman or ted iwas
Phone: 212-671-1020

Source link